STOCK TITAN

Arrowhead Pharma - ARWR STOCK NEWS

Welcome to our dedicated page for Arrowhead Pharma news (Ticker: ARWR), a resource for investors and traders seeking the latest updates and insights on Arrowhead Pharma stock.

Arrowhead Pharmaceuticals Inc. (ARWR) is a clinical-stage biotechnology leader developing RNA interference (RNAi) therapies that target disease-causing genes. This page provides investors and industry professionals with verified updates on the company's progress in advancing treatments for genetic disorders through its proprietary TRIM™ delivery platform.

Access consolidated, factual reporting of Arrowhead's material developments including clinical trial milestones, regulatory submissions, research collaborations, and financial disclosures. Our news aggregation ensures efficient tracking of therapeutic advancements in hepatitis B, cardiovascular diseases, and rare genetic conditions.

All content undergoes strict verification to maintain compliance with financial reporting standards. For stakeholders monitoring RNAi innovation and precision medicine breakthroughs, this resource offers centralized access to essential updates without speculative commentary.

Bookmark this page for streamlined monitoring of Arrowhead's progress in developing targeted gene silencing therapies. Check regularly for authoritative reporting on pipeline developments and strategic initiatives shaping the future of RNA-based medicine.

Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced positive interim results from the AROAAT2002 study, showcasing 48-week liver biopsy outcomes for the investigational RNAi therapeutic ARO-AAT, developed in collaboration with Takeda. The study observed significant reductions in mutant AAT protein levels, with a median decrease of 80.1% in total Z-AAT. Patients also showed improvements in liver fibrosis, with 6 out of 9 achieving stage improvements. ARO-AAT was well tolerated, indicating a promising therapeutic option for patients suffering from alpha-1 antitrypsin deficiency.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) presented promising preclinical data for ARO-DUX4, an RNA interference therapeutic targeting facioscapulohumeral muscular dystrophy (FSHD) at the 28th Annual FSHD Society International Research Congress. The company plans to seek regulatory approval in Q3 2021 to commence clinical trials. ARO-DUX4 demonstrated deep knockdown of DUX4 in mouse models, preventing muscle degeneration and related symptoms. The therapy addresses a significant unmet need in FSHD, where no effective treatments exist.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
-
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced positive interim results from the Phase 1/2 study of ARO-HSD, an RNA interference therapeutic targeting liver diseases, including nonalcoholic steatohepatitis (NASH). The study showed a mean 84% reduction in hepatic HSD17B13 mRNA and an average 46% decrease in alanine aminotransferase (ALT) levels after just two doses. The treatment was well-tolerated, with no significant safety concerns reported. These findings position ARO-HSD as a promising candidate for later-stage clinical studies, reinforcing HSD17B13's role as a therapeutic target.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
Rhea-AI Summary

Arrowhead Pharmaceuticals and Horizon Therapeutics have entered into a global collaboration for ARO-XDH, an investigational RNAi therapeutic for uncontrolled gout. Arrowhead will handle preclinical development, while Horizon will manage clinical development and commercialization. Arrowhead will receive $40 million upfront, with potential total milestone payments of up to $660 million plus royalties in the low- to mid-teens range on product sales. This partnership aims to address the unmet treatment needs in gout, affecting over nine million patients in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.87%
Tags
none
-
Rhea-AI Summary

Arrowhead Pharmaceuticals and Horizon Therapeutics have formed a global collaboration for ARO-XDH, an investigational RNA interference therapy aimed at treating uncontrolled gout. Under the agreement, Arrowhead will manage preclinical development, while Horizon will handle clinical development and commercialization. Arrowhead will receive an upfront payment of $40 million and could earn up to $660 million in milestones, plus royalties on sales. The partnership aims to address the significant unmet treatment needs in gout, affecting over nine million patients in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.87%
Tags
none
-
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has commenced patient dosing in the Phase 2b trial AROAPOC3-2001 to evaluate ARO-APOC3, aimed at treating severe hypertriglyceridemia (SHTG). The study will involve around 300 participants with triglyceride levels ≥ 500 mg/dL. Initial Phase 1 results suggested ARO-APOC3 could reduce triglyceride levels by up to 92%, maintaining efficacy for over 12 weeks. This trial seeks to determine the optimal dosing for future studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced its participation in several key upcoming events in June 2021. Highlights include:

  • Jefferies Virtual Healthcare Conference: June 3, 2:30 p.m. ET - Fireside chat with CEO Chris Anzalone.
  • Goldman Sachs Global Healthcare Conference: June 10, 2:10 p.m. ET - Fireside chat with CEO Chris Anzalone.
  • The International Liver Congress 2021: June 23-26 - Presentations on ARO-HSD and ARO-AAT, among others.

For more details, visit Arrowhead's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
conferences
-
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported that Janssen Pharmaceuticals has exercised its option for ARO-JNJ1, leading to a $10 million option exercise fee for Arrowhead. This agreement, part of a collaboration initiated in 2018, allows Janssen to develop and commercialize ARO-JNJ1, an RNAi therapeutic candidate. Arrowhead anticipates additional milestone payments and royalties from the commercial sales of ARO-JNJ1. The CEO expressed optimism about the collaboration, highlighting its productivity in addressing chronic hepatitis B and potential future programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
none
-
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) is set to participate in major healthcare events in May 2021. Key dates include the RBC Capital Markets Global Healthcare from May 18-20, with a presentation by CEO Chris Anzalone on May 18 at 11:30 a.m. ET, and the UBS Global Healthcare Virtual Conference from May 24-26, featuring another chat by Anzalone on May 26 at 3:00 p.m. ET. For presentation materials and details, visit the Arrowhead website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
conferences
Rhea-AI Summary

Arrowhead Pharmaceuticals (ARWR) reported its fiscal second-quarter financials for the period ending March 31, 2021. The company achieved a revenue of $32.8 million, up from $23.5 million in the previous year, resulting in a net loss of $26.8 million compared to $19.8 million in the same quarter last year. Operating expenses increased to $61 million, driven by research and development costs. Significant clinical updates include positive interim results for the ARO-AAT therapy and submissions for INDs for ARO-ANG3 and ARO-APOC3 treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags

FAQ

What is the current stock price of Arrowhead Pharma (ARWR)?

The current stock price of Arrowhead Pharma (ARWR) is $13.47 as of April 29, 2025.

What is the market cap of Arrowhead Pharma (ARWR)?

The market cap of Arrowhead Pharma (ARWR) is approximately 1.7B.
Arrowhead Pharma

Nasdaq:ARWR

ARWR Rankings

ARWR Stock Data

1.66B
119.34M
13.2%
74.66%
6.7%
Biotechnology
Pharmaceutical Preparations
Link
United States
PASADENA